A HMGCR polymorphism is associated with relations between blood pressure and urinary sodium and potassium ratio in the Epic-Norfolk Study

Journal of the American Society of Hypertension

Volumn 3, Issue 4, 2009, Pages 238-244

  Freitas, Renata N ^a,b   Khaw, Kay Tee ^b   Wu, Kelvin ^c   Bowman, Richard ^c   Jeffery, Hannah ^c   Luben, Robert ^b   Wareham, Nick J ^b   Bingham, Sheila A ^b,c  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

3 Hydroxy 3 Methylglutaryl coenzyme A reductase; diastolic blood pressure; genetic polymorphism; systolic blood pressure

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; POTASSIUM; SODIUM;

ADULT; AGED; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 67650720601     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.05.001     Document Type: Article

References (48)

1. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
2. Wierzbicki A.S. Lipid lowering: another method of reducing blood pressure?. J Hum Hypertens 16 (2002) 753-760
3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3342
4. Leitersdorf E., Hwang M., and Luskey K.L. ScrFI polymorphism in the 2nd intron of the HMGCR gene [abstract]. Nucleic Acids Res 18 (1990) 5584
5. Leitersdorf E., and Luskey K.L. HgiAI polymorphism near the HMGCR promoter [abstract]. Nucleic Acids Res 18 (1990) 5584
6. Zuliani G., and Hobbs H.H. A high frequency of length polymorphism in repeated sequences adjacent to Alu sequences. Am J Hum Genet 46 (2008) 963-969
7. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton Jr. V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
8. Strehlow K., Wassmann S., Böhm M., and Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 32 (2000) 386-389
9. Park H.-J., Kong D., Iruela-Arispe L., Begley U., Tang D., and Galper J. 3-Hydroxy-3-Methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circulation Res 91 (2002) 143-150
10. Ichiki T., Takeda K., Tokunou T., Iino N., Egashira K., Shimokawa H., et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21 (2001) 1896-1901
11. Hubacek J.A., Pistulková H., Valenta Z., and Poledne R. (TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia. VASA 28 (1999) 169-171
12. Plat J., and Mensink R.P. Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP, and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption. Eur J Clin Invest 32 (2002) 242-250
13. Tong Y., Zhang S., Li H., Su Z., Kong X., Liu H., et al. 8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease. Lipids 39 (2004) 239-241
14. Rasmussen M.S., Simonsen J.A., Sandgaard N.C.F., Hoilund-Carlsen P.F., and Bie P. Mechanisms of acute natriuresis in normal humans on low sodium diet. J Physiol 546 (2003) 591-603
15. Bie P., and Sandgaard N.C.F. Determinants of the natriuresis after acute, slow sodium loading in conscious dogs. Am J Physiol Regul Integr Comp Physiol 278 (2000) R1-R10
16. Sandgaard N.C.F., Andersen J.L., and Bie P. Hormonal regulation of renal sodium and water excretion during normotensive sodium loading in conscious dogs. Am J Physiol Regul Integr Comp Physiol 278 (2000) R11-R18
17. Graudal N.A., Galloe A.M., and Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglycerides. JAMA 279 (1998) 1383-1391
18. Hunt S.C., Geleijnse J.M., Wu L.L., Witteman J.C., Williams R.R., and Grobbee D.E. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am J Hypertens 12 (1999) 460-466
19. Johnson A.G., Nguyen T.V., and Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens 19 (2001) 1053-1060
20. Norat T., Bowman R., Luben R., Welch A., Khaw K.T., Wareham N., et al. Blood pressure and interactions between the angiotensin polymorphism AGT M235T and sodium intake: a cross-sectional population study. Am J Clin Nutr 88 (2008) 392-397
21. Khaw K.T., Bingham S., Welch A., Luben R., O'Brien E., Wareham N., et al. Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). Am J Clin Nutr 80 (2004) 1397-1403
22. Wareham N.J., Jakes R.W., Rennie K.L., Schuit J., Mitchell J., Hennings S., et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Public Health Nutr 6 (2003) 407-413
23. Ahmadian A., Gharizadeh B., Gustafsson A.C., Sterky F., Nyren P., Uhlen M., et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 280 (2000) 103-110
24. Nyren P., Karamohamed S., and Ronaghi M. Detection of single-base changes using a bioluminometric primer extension assay. Anal Biochem 244 (1997) 367-373
25. Ronaghi M., Karamohamed S., Pettersson B., Uhlen M., and Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242 (1996) 84-89
26. Amarenco P., Lavallee P., and Touboul P.J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 3 (2004) 271-278
27. Bellosta S., Ferri N., Bernini F., Paoletti R., and Corsini A. Non-lipid-related effects of statins. Ann Med 32 (2000) 164-176
28. Glorioso N., Troffa C., Filigheddu F., Dettori F., Soro A., Parpaglia P.P., et al. Effect of the HMG-CoA Reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 34 (1999) 1281-1286
29. Golomb B.A., Dimsdale J.E., White H.L., Ritchie J.B., and Criqui M.H. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 168 (2008) 721-727
30. Paciaroni M., Hennerici M., Agnelli G., and Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 24 (2007) 170-182
31. Calhoun D.A., and Oparil S. The sexual dimorphism of high blood pressure. Cardiol Rev 6 (1998) 356-363
32. Huxley V.H. Sex and the cardiovascular system: the intriguing tale of how women and men regulate cardiovascular function differently. Adv Physiol Educ 31 (2007) 17-22
33. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
34. Bingham S.A., Gill C., Welch A., Cassidy A., Runswick S.A., Oakes S., et al. Validation of dietary assessment methods in the United Kingdom arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int J Epidemiol 26 (1997) S137-S151
35. Bellosta S., and Paoletti R. Statin therapy and prevention of stroke. Curr Atheroscler Rep 2 (2000) 181-182
36. Cooke G.E. Pharmacogenetics of multigenic disease: Heart disease as an example. Vascular Pharmacology 44 (2006) 66-74
37. Polisecki E., Muallem H., Maeda N., Peter I., Robertson M., McMahon A.D., et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200 (2008) 109-114
38. Schmitz G., and Drobnik W. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med 41 (2003) 581-589
39. Singer J.B., Holdaas H., Jardine A.G., Fellstrom B., Os I., Bermann G., et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 48 (2007) 2072-2078
40. Berko B.A. Gender-related differences in cardiomyopathy. Cardiovasc Clin 19 (1989) 285-300
41. Hartel U. Gender issues in the epidemiology of cardiovascular diseases. Ther Umsch 64 (2007) 297-304
42. McBride S.M., Flynn F.W., and Ren J. Cardiovascular alteration and treatment of hypertension: do men and women differ?. Endocrine 28 (2005) 199-207
43. Regitz-Zagrosek V., Lehmkuhl E., and Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 4 (2007) S162-S177
44. Hurwitz S., Fisher N.D., Ferri C., Hopkins P.N., Williams G.H., and Hollenberg N.K. Controlled analysis of blood pressure sensitivity to sodium intake: interactions with hypertension type. J Hypertens 21 (2003) 951-959
45. Hollenberg N.K., Moore T., Shoback D., Redgrave J., Rabinowe S., and Williams G.H. Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med 81 (1986) 412-418
46. Luft F.C., Miller J.Z., Cohen S.J., Fineberg N.S., and Weinberger M.H. Heritable aspects of salt sensitivity. Am J Cardiol 61 (1988) 1H-6
47. Wassmann S., Laufs U., Bäumer A.T., Müller K., Konkol C., Sauer H., et al. Mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac GTPase. Mol Pharmacol 59 (2001) 646-654
48. Rupérez M., Rodrigues-Díez R., Blanco-Colio L.M., Sánchez-López E., Rodríguez-Vita J., Esteban V., et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 50 (2007) 377-383